Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

Financials (€)
Sales 2015 6,97 M
EBIT 2015 -16,3 M
Net income 2015 -17,4 M
Debt 2015 1,45 M
Yield 2015 -
Sales 2016 18,4 M
EBIT 2016 -11,1 M
Net income 2016 -12,4 M
Finance 2016 0,70 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 31,8x
EV / Sales 2016 12,0x
Capitalization 220 M
More Financials
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
04/15Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
03/27 ONXEO : Expands Livatag® International Phase III Clinical Trial “ReLive&rd..
03/26 ONXEO : expands Livatag® international phase III clinical trial “ReLive&rd..
03/25 ONXEO : Combined Ordinary and Extraordinary General Meeting on April 15, 2015: P..
03/22 DARA BIOSCIENCES : Acquires Exclusive North American Rights to Oravig from Onxeo
03/19 ONXEO : Consolidates Its Intellectual Property with the Grant of New Patent Prot..
03/18 ONXEO : consolidates its Intellectual Property with the grant of new patent prot..
03/14 ONXEO : Updates on 2015 Business Outlook and Past Achievements
03/13 DARA BIOSCIENCES : Buys Exclusive North American Rights to Oravig from Onxeo
More news
Sector news : Pharmaceuticals - NEC
02:06a BAYER : HealthCare Expands Collaboration with Broad Institute of MIT and Harvard..
01:31a KYOWA HAKKO KIRIN : Completion of Construction for New Research Building in Fuji..
03/30 ACTAVIS : Amneal Signs Deal to Acquire the Generic Business of Actavis Australia
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes